CollabRx Teams with MedPage Today to Introduce Digital Tool for Patient-Specific Genomic Approaches to Cancer Treatment
08 Août 2012 - 1:01PM
Business Wire
Tegal Corporation (NASDAQ: TGAL) today announced that its
recently acquired CollabRx, Inc., subsidiary signed an exclusive
license agreement to provide a version of its proprietary Therapy
Finder™ tool to MedPage Today, Everyday Health, Inc.’s rapidly
growing online site that serves 96% of all oncologists and 1.6
million monthly online unique users.
CollabRx is a cloud-based genomic information company that
enables physicians to take into account a tumor’s genetic profile
when considering targeted therapies in patient-specific cancer
treatments. To be launched today exclusively at
www.MedPageToday.com/Oncology-Next as “Oncology Next”, the CollabRx
tool leverages recent years’ dramatic increase in tumor genetic
data, which in turn has resulted in a parallel increase in the
development of cancer therapies that target specific genetic
profiles.
CollabRx has developed clinical advisory networks, expert
systems, proprietary tools and processes, and a pipeline of
commercial data products and applications (“apps”). CollabRx
Therapy Finders™ are web-based apps that serve as one type of user
interface to access proprietary CollabRx content, which is
dynamically updated and organized in a knowledgebase that includes
information on molecular diagnostics, medical tests, clinical
trials, drugs, biologics and other information relevant for cancer
treatment planning. CollabRx content is supported by a network of
over 50 of the top clinical practitioners in the United States.
“Oncology Next” will bring CollabRx proprietary content to
registered physicians of MedPage Today, which attracted over 1.6
million unique visitors in June 2012 (comScore), making it one of
the top healthcare professional websites in the U.S. “Oncology
Next” will be available initially as a free digital
decision-support service focusing on treatment of lung cancer.
Subsequently on a rolling basis, “Oncology Next” is to deliver
information on treatment of melanoma, colorectal cancer and breast
cancer.
“Oncology Next” is a free service to help physicians choose well
for their patients. Everyday Health and MedPage Today will offer
sponsorships and lead generation tools to major healthcare
companies in connection with this initiative. In addition to
licence fees, a portion of the revenue generated by sponsorships is
to be shared with CollabRx.
“The medical doctors and scientists at CollabRx have created
this breakthrough tool, and MedPage Today has the strongest
platform to reach physicians and help change cancer patient
outcomes,” said James Karis, CEO of CollabRx, Inc. and Co-CEO of
Tegal Corporation.1 “The CollabRx strategy is to develop
partnerships with key players that have the greatest reach to
multiple health care market segments. We are excited to be able to
announce our first partnership with the leading digital resource
for healthcare professionals.”
“MedPage Today’s partnership with CollabRx illustrates our
commitment to providing innovative and state-of-the-art tools for
physicians,” explained Ben Wolin, CEO and Co-Founder Everyday
Health, Inc. “’Oncology Next’ provides the community of oncologists
free access to medical and scientific advances in genomic medicine
to better inform their treatment planning for their patients.”
The companion announcement from Everyday Health is available on
Everyday Health, Inc.’s corporate website: EverydayHealthInc.com
and the CollabRx website.
About Tegal
Since its founding in 1972, Tegal Corporation has been dedicated
to the development and application of emerging technologies. For 40
years, Tegal’s process and equipment know-how has been incorporated
in devices fabricated by some of the world’s leading semiconductor
and MEMS companies, including Tegal’s one-time parent, Motorola.
Now entering its fifth decade, Tegal has committed its future to
the CollabRx vision of “Informing Next Generation Healthcare”.
Please visit us on the web at www.tegal.com.
About CollabRx
CollabRx is a recognized leader in “cloud-based” expert systems
to inform health care decision-making. CollabRx uses information
technology to aggregate and contextualize the world's knowledge on
genomics-based medicine with specific insights from the nation's
top cancer experts starting with the area of greatest need:
advanced cancers in patients who have effectively exhausted the
standard of care. More information may be found at
www.collabrx.com.
About MedPage Today
MedPage Today is the fastest growing news organization serving
healthcare professionals (comScore.)The company's daily,
peer-reviewed news coverage delivered via the web and several
mobile applications allows healthcare professionals to put breaking
medical news into practice. MedPage Today also offers coverage of
health conferences from around the world in almost any specialty,
and physicians can access live video interviews and dialogues to
encourage conversation and better health outcomes. Medpage Today
had over 1.6 million unique visitors in June 2012(comScore), making
it one of the top HCP website in the U.S.
About Everyday Health, Inc.
Everyday Health is the leading new media health company.
Attracting 38 million people monthly through its popular websites,
mobile applications, and social media presence, Everyday Health
inspires consumers to live healthier lives and helps doctors make
more informed decisions for their patients. Everyday Health reaches
an additional one million viewers per episode through its weekly TV
series on ABC stations. The Company’s broad portfolio of products
spans the health spectrum, from in-depth medical content for
condition prevention and management to healthy lifestyle offerings.
Everyday Health was founded in 2002 by CEO, Ben Wolin, and
President, Mike Keriakos.
Source: comScore Media Metrix; comScore Video Metrix; Facebook
Insights; Twitter.
Safe Harbor Statement
This press release contains forward-looking statements that may
include statements regarding the intent, belief or current
expectations of Tegal, CollabRx and their respective management.
Forward looking statements include statements about the benefits
and advantages of the acquisition for Tegal and CollabRx. Actual
results could differ materially from those projected in the
forward-looking statements as a result of a number of important
factors, including but not limited to the risk that the acquisition
will not close as the transaction is subject to certain closing
conditions. In addition, if and when the transaction is closed,
there will be risks and uncertainties related to Tegal’s ability to
integrate CollabRx successfully, the risk that the anticipated
benefits from the acquisition may not be fully realized or may take
longer to realize than expected; and competition and its effect on
the combined company’s performance. Additional factors that may
affect future results are contained in the SEC filings for Tegal,
including but not limited to Tegal’s Annual Report on Form 10-K for
the year ended March 31, 2012. Tegal and CollabRx each disclaim any
obligation to update and revise statements contained in this
release based on new information or otherwise.
1 Since the July 12 acquisition of CollabRx, Tegal has announced
that it intends to continue to operate under its current name and
ticker symbol for the time being, but plans to seek stockholder
approval at its upcoming annual meeting on September 25, 2012 for
an amendment to its Certificate of Incorporation, changing its
corporate name to CollabRx, Inc.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50370240&lang=en
Tegal (NASDAQ:TGAL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Tegal (NASDAQ:TGAL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024